FDA Accepts Nanoscopes's Optogenetic Gene Therapy BLA
The FDA accepts a biologics license application (BLA) for a first-of-its-kind optogenetic gene therapy for RP; a software upgrade from Heru combines several pretesting assessments into a single guided workflow; and a new FDA-approved overnight orthokeratology lens is launched in the US. Learn more about your ad choices. Visit megaphone.fm/adchoices
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Eyewire News: The Podcast
Breaking News From the ESCRS Congress in London (Part 1 of 2)
FDA Sets PDUFA Date for Investigational Glaucoma Eye Drop
EyePoint Misses Primary Endpoint in Phase 3 Trial But Sees Promise After Analysis
Three Major Acquisitions Announced in Ophthalmology
Get summaries like this every morning.
Free AI-powered recaps of Eyewire News: The Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.